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ABSTRACT
Non-natural peptide mimics are referred to as peptidomimetics, which contains unnatural
backbones that mimic the primary peptide structure. There are a large number of peptidomimetics
that have been developed including α-peptides, β-peptides, peptoids, arylamide oligomers, cationic
polymers, and other peptidomimetics in the last decades. Compared to conventional peptides, these
peptidomimetics have many advantages such as resistance to proteolysis, improved bioavailability,
and reduced immunogenicity. However, the development of peptidomimetics is still far below the
expectation due to the limitation of the availability of backbones. It is an urgent need to generate
a new diverse library for novel drug discovery, design antimicrobial agents, and disrupt proteinprotein interaction, etc. In the commitment to the development of a new class of peptidomimetics,
our group describes a family of chemically diverse peptidomimetics based on the backbone of γchiral peptide nucleic acid (γ-PNA). They are termed “γ -AApeptides” because they are comprised
of γ -substituted-N-acylated-N-aminoethyl amino acids.
In this dissertation, I explored the development of three key aspects of γ-AApeptides. Firstly, the
lipo-γ-AApeptides as a new class of antimicrobial peptidomimetics that mimic the bactericidal
functions of Host-defense peptides (HDPs). Secondly, γ-AApeptides applied to the development
of combinatorial chemistry. Finally, the synthetic γ-AApeptide as protein mimics. The findings in
this dissertation may lead to the development of a new class of antimicrobial agents and novel drug
discovery.

viii

CHAPTER 1: INTRODUCTION
γ-AApeptide
Peptidomimetics such as α-peptides, β-peptides, peptoids, arylamide oligomers, cationic polymers,
and others have been explored in the past several decades [1]. These peptidomimetics are highly
resistant to protease degradation, thus can be potentially orally available. Also, the large chemical
and structural diversity of peptidomimetics may lead to simpler compounds that are less costly to
manufacture but exhibit higher potency and selectivity. Our group has reported a class of
peptidomimetics “γ-AApeptide”, γ-AApeptide are oligomers of N-acylated-N-aminoethyl amino
acids from γ-chiral peptide nucleic acid (γ-PNA) (Figure 1.1) [2]. We choose γ-PNA backbones
as the starting structure because of their superior resistance to proteolysis and their potential for
peptide mimicry [3]. In γ-AApeptide, nitrogen atoms on the backbone are either forming secondary
or tertiary amide bonds. γ-AApeptide side chains on the γ position of the backbone are derived
from α-amino acids. Compared with conventional α-peptides, γ-AApeptide is able to project the
same number of side functional groups on the backbone of same length [4]. Therefore, γAApeptide are presumably able to mimic peptide structures and reproduce their functions, and
generate a novel chemically diverse library for drug discovery [5].
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Figure 1. 1 The structures of a γ-AApeptide as comparison with an α-amino acid.

Antibacterial Resistance (ABR)
Due to the misuse and overuse of antibiotics, the antibiotic resistance is one of the most serious
problem that threatens human health. More than 2 million people every year are infected with
antibiotic-resistant infections in the United States alone [6].
There are four main categories of antimicrobial resistance mechanisms:(1) limiting the uptake of
a drug; (2) modifying the drugs target; (3) inactivating a drug; (4) or activating drug efflux.
Intrinsic resistance may use limiting drug uptake, drug inactivation, and drug efflux. While
acquired resistance mechanisms may include drug target modification, drug inactivation, and drug
efflux. There is variation in the types of mechanisms used by gram negative bacteria versus gram
positive bacteria due to the difference in structure [7].

Figure 1. 2 General antimicrobial resistance mechanisms [7]. (The figure was reproduced with
permission of AIMS Press.)
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Gram-positive vs Gram-negative Bacteria
Bacteria are classified into Gram-positive and Gram-negative based on their cell-wall properties.
From Figure 1.3, Gram-positive cell walls contain only one lipid plasma membrane and a thick
peptidoglycan layer interlinked with teichoic and lipoteichoic acids. Whereas Gram-negative
bacteria have an inner and an outer cell membrane with a thin layer of peptidoglycan in the
periplasmic space between the inner and outer membrane. Also, Gram-negative bacteria contain
lipopolysaccharide on the surface of their out membrane [8].

Figure 1. 3 Schematic structure of Gram-positive and Gram-negative cell walls [8].( The figure
was reproduced from Atterx Biotherapeutics. Gram-negative vs. Gram-positive bacteria.
http://atterx.com/gn-4474/Cerner M. Isopropyl Alcohol: Uses, Side Effects and Interactions.
Drugs. 2019 )

Host Defense Peptides (HDPs)
Host-defense peptides (HDPs) have been developed in past decades, they are natural cationic
amphiphilic peptides found in all organisms and act as the first line of nonspecific defense to
against a variety of pathogens including bacteria, fungi, and virus [9]. Unlike traditional antibiotics
target and breakdown intracellular components of bacteria or specific cell wall, HDPs interact with
bacterial membranes firstly with the cationic groups interacting with the negatively charged
bacterial membranes [10]. After that, the HDPs’ hydrophobic residues interact with the fatty acyl
3

tails of membrane phospholipids causes bacterial membrane penetration, depolarization, and
disruption [11]. HDPs are acting with bacterial membranes in biophysics and no defined specific
membrane targets, these characters help HDPs have much lower antibiotic resistance compared to
traditional antibiotics [12]. Consequently, HDPs are a potential and viable strategy to develop new
antibiotic agents. However, there are several inherent drawbacks that limit the clinical
development of HDPs, such as high production cost, low in-vivo stability, and toxicity to
eukaryotic cells [13].

Figure 1. 4 Models of peptide-induced membrane disruption or interfacial activity. [14] (The
figure was reproduced with permission of Elsevier.)

γ-AApeptide Library
Combinatorial chemistry is a methodology by which we can simultaneously synthesize a large
number of possible compounds through the use of a large number of building blocks. It is widely
used in pharmaceutical, agrochemical, and biotechnology industries as a key technology for
accelerating the discovery of novel therapeutic agents.
In recent years, our group has devoted to the development of the γ-AApeptides-based
combinational libraries to expand the biological potential of γ-AApeptides. At the start, we
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designed and synthesis the one-bead-one-compound (OBOC) linear γ-AApeptides-based
combinational libraries [15].
We synthesized the library by the split-and-pool method （Figure 1.5）. As shown in Figure 1.6,
we first attached a methionine residue on the TentaGel, which facilitates the cleavage from beads
by CNBr treatment. Then four kinds of N-alloc-protected γ-AApeptides building blocks and five
kinds of acylating agents were attached to generate four -building block γ-AApeptides library.
There is only one compound displayed on one bead at the end. Accounting from our group
previously published papers, it is demonstrated the OBOC linear γ-AApeptides-based
combinational libraries have the capability as molecular probes or therapeutic agents [15, 16].

Figure 1. 5 Use of combinatorial chemistry to generate a compound library. This diagram shows
one technique, split mix synthesis, for generating large numbers of compounds [17]. (The figure
was reproduced with permission of Wolters Kluwer Health, Inc.)
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Figure 1. 6 The preparation of γ-AApeptide OBOC library. The diversity of the library: totally 4
× 5 × 4 × 5 × 4 × 5 × 4 × 5 = 160,000 compounds. Beads: TentaGel MB NH2, particle size: 140 170 μm, capacity: 0.5 nmol/bead [16]. (The figure was reproduced with permission of Royal
Society of Chemistry.)

We thus committed to the macrocyclic combinatorial library design. Based on the structure
chemistry, the macrocyclic γ-AApeptides are more stable against proteolytic degradation and
contain more bioavailable compared to linear γ-AApeptides. For the cyclic library design, we
included a thioether moiety as thioether -bridge mediated cyclization since it is common structure
6

in some proteins and natural products. Also, we confirmed that the thioether bridged cyclic γAApeptides is more conformationally rigid than that of the linear one [18].
For the cyclic library synthesis, we included hydrophobic, cationic and negatively charged side
chains, five different N-Alloc protected γ-AApeptide building blocks (Figure 1.7). Unlike linear
γ-AApeptide library, the one-bead-two-compound (OBTC) library containing both cyclic
sequence and analyzable coding linear sequence on the same bead since the cyclic γ-AApeptide
structure can’t be decode by MS/MS directly. The coding peptide is composed of α-amino acids
which can be easy and unambiguously decoded by MS/MS. After repeated attempts, we finally
found that Dde (1-(4,4-dimethyl-2,6-dioxacyclohexylidene)ethyl) protected α-amino acids for the
coding peptide synthesis would easily allow for this. The deprotection condition of Dde is mild by
using NH2OH·HCl and imidazole without affect the cyclic sequence synthesis [19].

Figure 1. 7 Synthesis of the thioether bridged one-bead–two-compound macrocyclic γ-AApeptide
library. (The figure was reproduced with permission of American Chemical Society)

7

Outline of the Dissertation
In chapter 2, lipo-α/sulfono- γ-AA hybrid peptides were reported. These peptides are easy to be
synthesized, the lead sequences display potent and broad-spectrum antimicrobial activity against
a series of Gram-positive and Gram-negative bacteria.
In chapter 3, we used the dimerization strategy to design and synthesis a series of dimeric lipoα/sulfono- γ-AA hybrid peptides, these peptides show stronger antimicrobial activity compared to
the monomer compounds. The further development of the class of dimerized γ-AA peptides could
lead to a new generation of antibacterial agents.
In chapter 4, one-bead-one-compound (OBOC) linear γ-AApeptides-based combinational library
screened against Aβ aggregation which is one of the major causations of Alzheimer's disease (AD).
The lead compound HW-155-1 was identified and proved to have the ability to inhibit Aβ
aggregation.[9] Then, we designed and synthesized the dimer compound HW-C-9 as a potential
molecular probe or therapeutic agent for the treatment of Alzheimer’s disease (AD).
In chapter 5, the Epidermal growth factor receptor (EGFR) is the receptor for epithelial growth
factor (EGF) cell proliferation and signal transduction. Studies have shown that there is a high or
abnormal expression of EGFR in many tumors. We synthesized one-bead–two-compound (OBTC)
macrocyclic γ-AApeptide library screened against EGFR and identified the novel molecule M-25 can tightly binds to EGFR to inhibit its autophosphorylation. Then, we designed and synthesized
the dimer compound C-30 to further study on against EGFR.
In chapter 6, we designed and synthesized the lipo-α/sulfono- γ-AA hybrid peptides mimic the
Gastric inhibitory polypeptide（GIP）as a potential novel drug which can be in the treatment of
type 2 diabetes and obesity
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CHAPTER 2: ANTIBACTERIAL ACTIVITY OF LIPO- α/SULFONO- γ-AA HYBRID
PEPTIDES
Note to Reader
Contents in this chapter have been previously published in European Journal of Medicinal
Chemistry, 186 (2020) 111901, and have been reproduced with the permission of the Elsevier.
Introduction
Antimicrobial resistance is one of the greatest threats to public health [1]. Among them, multidrugresistant bacterial strains, such as Gram-positive bacteria methicillin-resistant Staphylococcus
epidermidis (MRSE), methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus faecalis
(E. faecalis), Gram-negative bacteria Escherichia coli (E. coli), and Pseudomonas aeruginosa
(PA), have caused severe and even lethal infections [2, 3]. Thus, the development of new
generations of antibiotics is of considerable significance.
Host-defense peptides (HDPs) developed in recent decades have been recognized as a potential
approach to combat bacterial resistance [1, 4, 5]. Due to their antimicrobial mechanism of action
which selectively compromises bacterial membranes, HDPs have shown good selectivity for
bacteria and are believed to have lower tendency to induce antibiotic resistance than traditional
antibiotics[2, 6]. However, some inherent drawbacks still remain in the development of HDPs,
such as susceptibility to proteolytic degradation and low-to-moderate activity [7, 8]. New
generations of antibiotic agents with minimal probability for resistance selection, as well as
enhanced activity and stability, are still in an urgent need [3]. Among them, mimicry of the
11

mechanism of action of HDPs by peptidomimetics is one of the viable strategies [8]. To date
antimicrobial peptidomimetics, including β-peptides [9], peptoid-peptide hybrids [10], peptoids
[11], acrylamide oligomers [12], and others, are reported [13]. Recently, our group has developed
a new class of peptidomimetics termed “γ-AApeptides,” as they are oligomers of N-acylated-Naminoethyl amino acids (Figure 2.1) [13, 14]. We have designed a variety of γ-AApeptide
derivatives to mimic the amphipathic structure of HDPs, and some of them exhibited excellent and
broad activity against both Gram-positive and Gram-negative bacteria [15-22]. Among them, it is
interesting that short antimicrobial peptide hybrids, containing α-amino acid units and γ-AA
residues, exhibit potent antimicrobial activity and selectivity [22]. It is noted that compounds with
small molecular weight are expected to be more drug-like molecules. As such, we intended to
further explore the potential of this type of peptide hybrids for antimicrobial applications. Our
previous findings[23] and other research groups[24, 25] reveal that peptides/peptidomimetics with
addition of a hydrophobic tail could enhance the interaction between peptides and bacterial
membranes because the hydrophobic tail increases the lipophilicity of peptides. Herein we report
the design and synthesis of short lipo-α/sulfono-γ-AA hybrid peptides, as well as their
antimicrobial activity [26, 27].

Figure 2. 1 General structures of canonical α-peptides, γ-AApeptides, sulfono-γ- AApeptides, and
α/sulfono-γ-AA hybrid peptides.
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Results and Discussion
We synthesized a series of short lipo-α/sulfono-γ-AA hybrid peptides on the solid phase and
purified by HPLC adapted from previously reported protocols [28] (see Experimental Section for
details). These peptides contain one or two amphiphilic sulfono-γ-AA peptide building blocks, and
some of them have one additional lysine amino acid residue (Figure 2.2). The lysine side chains
provide positive charges whereas aromatic side chains are used as hydrophobic groups.
Meanwhile, A lipid tail was conjugated at N terminus or C terminus to presumably increase their
antibacterial activity.

Figure 2. 2 The structures of compounds 1–11.
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Table 2. 1 Antibacterial activity of compounds 1–11. The bacteria used were methicillin-resistant
S. aureus (MRSA) (ATCC 33591), methicillin-resistant S. epidermidis (MRSE) (RP62A),
vancomycin-resistant E. faecalis (ATCC 700802), E. coli (ATCC 25922), P. aeruginosa (ATCC
27853). Hemolysis activity was not measured for peptidomimetics that did not show antimicrobial
activity for all tested strains.
Compound

MIC (μg/mL)

Gram-positive

Hemoly

Selectivity

sis

(HC50/MIC

Gram-negative
(HC50,

MRSA)

μg/mL)

MRSA MRSE

E.

E. coli

P. aeruginosa

faecalis
1

5

8

5

>50

>50

NT

2

5

5

5

5

20

NT

3

5

20

5

5

>50

NT

4

5

20

5

5

>50

NT

5

>50

>50

>50

>50

>50

NT

6

20

20

>50

5

8

NT

7

5

5

5

2

5

125

14

25

Table 2.1 (Continued)
8

2

20

5

>50

>50

NT

9

8

20

8

>50

>50

NT

10

2

5

5

8

8

50

25

11

2

5

8

5

5

100

50

Ciprofloxaci

0.5

0.5

0.5

1

1

NT

NT

n

Table 2.1 displays antimicrobial activity and hemolytic activity for each short lipo-α/sulfono-γAA hybrid peptide. As shown in Table 1, the first sequence 1, containing just one sulfono-γ-AA
building block and a C16 lipid tail, already exhibited good activity toward Gram-positive bacteria.
The sequence 2, with one lysine residue, displayed activity toward both Gram-positive and Gramnegative bacteria, suggesting the importance of peptide hybrid backbone [26, 29]. Introduction of
the C16 lipid tail at the C-terminus of both 1 and 2 leading to sequences 3, and 4. Interestingly,
these two lipidated sequences show similar antibacterial activity to 1 and 2. This result suggested
that lipidation on either N or C terminus would not affect antibacterial activity of sequences.
To investigate the impact of the length of hydrophobic lipid tails, we next synthesized sequences
5-8. The sequence 5 bearing a C10 lipid tail did not show any antibacterial activity at all, which is
consistent to our previous findings that short lipid tails won’t interact with bacterial membranes
effectively [26, 28]. As expected, the sequence 6 started to show antibacterial activity, whereas 7,
bearing a C14 lipid tail, show the most potent and broad-spectrum antimicrobial activity toward
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all tested Gram-positive or Gram-negative bacteria strains. It is more potent than 2 and 8 that bear
C16 and C18 tails respectively, which suggests that this class of peptidomimetics has an optimal
length of lipid tail to interact with bacterial membranes most strongly. To test if extra sulfono-γAA building block could enhance the activity, we set out to synthesize sequences 9-11.
Intriguingly, none of these sequences show improved activity compared to 7, possibly due to the
different ratio of cationic/hydrophobic groups. In order to assess the selectivity of these short lipoα/sulfono-γ-AA hybrid peptides, we also tested hemolytic activity for the most potent compounds
7, 10 and 11 which exhibited broad-spectrum antimicrobial activity against almost all tested
strains. As shown in Table 2.1, These compounds show very good selectivity.
It is known that HDPs could eradicate bacteria rapidly due to their membrane-disruptive
bactericidal mechanism [30]. To determine the time of action and efficacy of our newly
synthesized compounds, the time-kill study was conducted to investigate if the most potent
compound 7 could rapidly kill MRSA and E. coli [31]. As shown in Figure 2.3, at 50 μg/mL,7
could eradicate all MRSA in just 10 min. Killing E. coli by 7 is comparatively slower, even though,
all bacteria were completely killed in 60 min at 50 or 25 μg/mL. This observation suggests that the
compound could kill both Gram-positive and Gram-negative pathogens rapidly, in a manner
similar to HDP.
According to a recent public statement from the National Institutes of Health, more than 65% of
all microbial infections are caused by biofilms [30]. It is known that bacteria in the biofilm are
commonly more arduous to destroy than independent cells. Also, biofilms can clog pipes,
watersheds, storage areas, and contaminate food products. In order to assess the possibility of the
hybrid peptides in the biofilm prevention, Compound 7 was evaluated for its capability to suppress
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the biofilm formation of E. coli. As shown in Figure 2.4, at just a concentration of 0.05 μg/mL,
compound 7 could eradicate almost 50% of biofilm formation of E. coil.

Figure 2. 3 Time-kill plots of 7 against MRSA (a) and E. coli (b).

Figure 2. 4 Biological activity of 7 in the inhibition of a biofilm by E. coli.

To further confirm that compound 7 disrupts the bacterial cell membrane integrity, we used
spectroscopic methods against both Gram-positive and Gram-negative bacteria to investigate the
antimicrobial

mechanism.

In

the

assay

of

membrane

depolarization,

we

utilized

3,3′dipropylthiadicarbocyanine iodide (DiSC35) which is a membrane-potential sensitive dye
[32]. Generally, the dye would become fluorescent when the membrane potential is lost. In Figure
2.5, Both MRSA and E. coli shows fluorescence intensity increase dramatically upon treatment of
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7 The result indicated that the membrane potential was lost due to the disruption of the bacterial
membranes.

Figure 2. 5 Membrane depolarization of MRSA (A) and E. coli (B). Negative control is the culture
without antibacterial treatment. The experiment was repeated three times with duplicates each
time.

Subsequently, we carried out fluorescent microscopic study to further assess the compounds’
impact on bacterial membranes. As we know, HDPs can compromise bacterial membranes to let
cell death. The compounds should also compromise bacterial membranes if they mimic the
mechanism of HDPs. As such, compound 7, the most potent compound, was chosen in the study.
4′,6-diamidino-2-phenylindole (DAPI) and propidium iodide (PI) were used as dyes in the assay.
The control, which was just MRSA or E. coli bacteria, shows blue fluorescence in the DAPI
channel (a1 and a3). However, they were not observed in the PI channel (b1 and b3) because their
membranes were intact [33]. After MRSA and E. coli were incubated with compound 7 for 2h,
they fluoresced in both DAPI and PI (a2,b2, a4, b4) channels. The result suggests the membranes
of both MRSA and E. coli were disrupted.
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Figure 2. 6 Fluorescence micrographs of MRSA and E. coli.They are treated or not treated with 6
μg/mL of compound 7 for 2 h: (a1) control, no treatment, DAPI stained; (b1) control, no treatment,
PI stained; (a2) MRSA treatment with 7, DAPI stained; (b2) MRSA treatment with 7, PI stained;
(a3) control, no treatment, DAPI stained; (b3) control, no treatment, PI stained;(a4) E. coli
treatment with 7, DAPI stained; (b4) E. coli treatment with 7, PI stained.

Conclusion
In conclusion, we designed and synthesized short sulfono lipo-a/sulfono-γ -AA hybrid peptides.
These sequences, bearing sulfono-γ-AA building blocks, a lysine amino acid residue and a
hydrophobic lipid tail, were able to be synthesized at ease. These compounds could interact with
bacteria membrane and kill bacteria in a manner similar to HDPs. The lead sequences display
potent and broad-spectrum antimicrobial activity against a series of Gram-positive and Gramnegative bacteria. Additionally, they also show little hemolytic toxicity and good potency to inhibit
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the formation of biofilms. The further development of this class of peptidomimetic could lead to a
new class of antimicrobial agents.

Experimental Procedure
General Information
Rink-amide resin (0.7 mmol/g, 200‒400 mesh), 2-Chlorotrityl chloride resin(0.97mmol/g,100-200
mesh) and Fmoc protected α-amino acids were purchased from Chem-Impex Int’l Inc. Solvents
and other chemicals were purchased from either Fisher Scientific or Sigma-Aldrich and used
without further purification. Solid-phase synthesis of the compounds in a peptide reaction vessel
on a Burrell wrist-action Shaker and purified on a Waters Breeze 2 HPLC system with both
analytical and preparative functions. HPLC fractions were collected and confirmed using a Bruker
AutoFlex MALDI-TOF mass spectrometer. The desired products and lyophilized on a Labcono
lyophilizer.
Synthesis of Sulfono-γ-AApeptide Building Blocks
The syntheses of the sulfono-γ-AApeptide Building Blocks (Figure 2.7) was followed the
previously reported procedure [34].

Building block 1

Building block 2

Building block 3

Figure 2. 7 Sulfono-γ-AApeptide building blocks used in the study.
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Boc-Lys(Boc)-OH

Synthesis of Desired α/Sulfono-γ-AA Hybrid Peptides
Synthesis of Compound 3 [34]
Building block 2 (0.3 mmol) and 1.5 equivalent of 1-Hexadecanamine were dissolved in DCM in
a 50 mL round bottom flask, to which3 equivalent of TBTU, 3 equivalent of HOBt, and 5
equivalent of DMAP were added. The resulted solution was allowed to stir overnight. Then the
solution was washed with 0.1 M HCl three times, water, and brine. The organic layer was collected,
dried over anhydrous Na2SO4, and then the solvent was removed by vacuum. The residue was
nexttreated with 2 mL DCM/TFA (1:1) for 1 h to remove Boc protecting group. The crude
compound 3 was purified on a Waters HPLC system, followed by lyophilization to give the pure
product 3.
Synthesis of Compound 4 [34]
2-Chlorotrityl chloride (CTC) resin (200 mg, 0.2 mmol) was allowed to swell in 2 mL of DCM for
15 min. The first attachment was conducted by adding building block 3 (0.3 mmol) and DIPEA
(0.3 mmol) to the beads in the reaction vessel, which was allowed to shake at room temperature
for 2 h. After that, the reaction solution was drained, followed by washing with DMF three times
and DCM three times. The unreacted residues were capped with 2 mL of methanol for 30 min.
After washed with DMF and DCM three times, the Alloc protecting group removed treated with
Pd(PPh3)4 (0.2 mmol) and Me2NH.BH3 (1.2 mmol) in 2 mL DCM for 10 min twice. After the
reaction, the solution was drained. The beads were washed with DCM and DMF three times, then
1.5 equivalent of Boc-Lys(Boc)-OH, 4 equivalent of HOBT and DIC in DMF were added and the
mixture was reacted for 4 h. The beads were washed with DMF and DCM three times, then used
4 mL cleavage cocktail (acetic acid : TFE : DCM = 1:1:8) to cleave from resin. After 2 h, the
solution was collected and concentrated by vacuum. The residue was then added with1.5
21

equivalent of 1-Hexadecanamine. followed by the addition of coupling reagents: 3 equivalent of
TBTU, 3 equivalent of HOBt, and 5 equivalent of DMAP in DCM. The reaction was allowed to
run overnight, and the solution with washed with 0.1 M HCl three times, water, and brine. DCM
layer was collected, dried over anhydrous Na2SO4, and the solvent was removed by vacuum. The
residue was treated with 2 mL DCM/TFA (1:1) for 1 h to remove Boc protecting group. The crude
compound 4 was purified on a Waters HPLC system, followed by lyophilization to give the pure
product 4.
Synthesis of Compound1-2 and 5-11 [27]
Others lipo-α/γ-AA hybrid peptides sequences were synthesized following the standard solid phase
peptide synthesis protocol by using Rink-amide resin. For every coupling step, 20% Piperidine in
DMF was first used to remove the Fmoc protecting group, then 1.5 equivalent of building block
1/ Fmoc-Lys(Boc)-OH / saturated fatty acids, 4 equivalent of HOBT and DIC in DMF were added
to react for 4 h. The assembled sequences were cleaved from the resin in 50:48:2 TFA/DCM/TIS
(triisopropylsilane) for 2 h. The solvent was removed by vacuum and the peptide sequences were
purified on a Waters HPLC system, followed by lyophilization to give the pure product.
NMR data
Compound 7 1H NMR (600 MHz, C2D6OS) δ 7.80 (d, J = 6 Hz, 1H),7.628 (s,5H),7.41(s,1H),
7.31(dd, J=23.28,6.37Hz,5H),7.13(s, 1H),4.39(d, J=1.92 Hz,2H),4.01(dd, J= 13.57,8.02Hz,1H)
3.81(dd,J=27.75,17.89Hz,3H),2.66(s,5H),2.04(t,J=6.8,2H),1.55(s,1H),1.341.5(m,8H),1.17(s,27H) ,0.79 (t, J=6.8, 3H).
C35H64N6O5S [M + H]+ calcd= 681.4659; found=681.4660
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Table 2. 2 MALDI analysis of lipo-α/sulfono-γ-AA hybrid peptides.
Lipo-α/γ-AA hybrid peptides

Molecular Weight (Actual)

Molecular Weight (observed)

1
2
3
4
5
6
7
8
9
10
11

580.87
709.05
566.89
695.07
624.89
652.94
680.99
737.10
906.30
1034.48
1006.42

581.9 (M+H+)
710.1 (M+H+)
567.9 (M+H+)
696.1 (M+H+)
625.9 (M+H+)
654.0 (M+H+)
681.1 (M+H+)
738.1 (M+H+)
907.3 (M+H+)
1035.5 (M+H+)
1007.5 (M+H+)

Minimum Inhibitory Concentrations (MICs) Antimicrobial assays [26]
We tested the antimicrobial activity of the 11 compounds on five different bacteria strains
including MRSA (ATCC 33591), MRSE (RP62A), E. faecalis (ATCC700802), P. aeruginosa
(ATCC27853), and E. coli (ATCC 25922). A single colony of each bacterial strain was inoculated
into 4 mL of TSB buffer at 37 °C overnight. Then the bacteria culture was diluted 100 times and
allowed to grow to the mid-logarithmic phase. 50 µL of these bacteria suspension were added into
50 µL of different concentrations of lipo-α/γ-AA hybrid peptides diluted using the same TSB
medium. The mixtures were incubated at 37 °C for 12-16 h, the absorption at 600 nm wavelength
on a Biotek Synergy HT microtiter plate reader was recorded. MICs are the lowest concentrations
of the compounds which can inhibit the bacteria growth. Results were repeated three times with
duplicates each time.
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Time-kill Assay [26]
The best compound 7 was tested the kinetics of bacteria killing. The bacteria MRSA (Grampositive) and E. coli (Gram-negative) suspensions were grown at 37 °C to the mid-logarithmic
phase in TSB medium and diluted to 1 × 106 CFU/mL, the suspension was incubated with the
compound 7 at the concentration of 12.5, 25, 50µg/mL for 10 min, 30 min, 1 h, and 2 h,
respectively. The mixtures were diluted by 102 to 104-fold, the colonies on the plates were counted
and plotted against the incubation time after overnight incubation at 37 ° C.
Fluorescence Microscopy [26]
DAPI (4’,6-diamidino-2-phenylindole dihydrochloride) and PI (propidium iodide) are two dyes
used to stain the bacterial membrane and visualized by fluorescence microscopy. As we know, PI
only stains dead cells since it can only pass through damaged membranes. However, DAPI can
dye any bacterial cells. The compound 7 was incubated with the bacteria at 37℃, the procedure of
7 is detailed below. Bacteria were grown to mid-logarithmic phase and incubated with the lipoα/sulfono-γ-AA hybrid peptide 7 at 10 µg/mL for 2 h. The culture centrifuged at 5000g for 15 min.
The pellets were washed with PBS, then incubated with PI (5 µg/mL), followed by PBS washing
three times, and then DAPI (10 µg/mL) incubation. Each dye incubation was incubated for 15 min
on ice in dark. The stained bacteria were observed under a Zeiss Axio Image Zloptical microscope.
Inhibition of Biofilms [30]
E. coli biofilms was grown at 37 °C for 24 h in 96-well plates in TSB in this assay. The wells were
washed three times with TSB to remove unattached or weakly attached biofilms.50uL of the
compound 7 solution (prepared by 2:1 serial dilution) in PBS and added fresh TSB to make up the
total volume of 100 uL. Then the plate was incubated at room temperature over 24h, the percentage
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of biofilm detachment was recorded at a wavelength of 600 nm by using a microtiter plate reader,
biofilm biomass was presented as CV OD/ OD of growth. Experiments were repeated at least three
times.
Bacterial Membrane Depolarization Assay [32]
Mid-log phase MRSA cells were collected and washed by using 5 mM HEPES and 5 mM glucose.
The bacteria was re-suspended in 5 mM glucose, 5 mM HEPES buffer, and 100 mM KCl solution
in 1:1:1 ratio (108 CFU/mL). 200 μL of bacterial suspension and 2 μM DiSC3(5) were incubated
in a 96-well plate at 37 °C, and the fluorescence of the suspension was monitored for 30 min at the
excitation wavelength of 622 nm and the emission wavelength of 670 nm. The concentration of 7
is 250 µg/mL. After the minimum value of the fluorescence (after 20 min) was reached, the
compound 7 was added to the wells, so as to monitor the decrease in potential by the increase in
fluorescence. The experiment was repeated at least three times with duplicates each time.
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CHAPTER 3: DIMERIC LIPO- α/SULFONO- γ-AA HYBRID PEPTIDES AS BROADSPECTRUM ANTIBIOTIC AGENT
Introduction
Conventional antibiotics have been used to treat bacterial infections for many years. However, the
misuse and overuse of antibiotics aggravate antibiotic resistance is one of the biggest issues to
threaten public health over the world [1, 2]. Multidrug-resistant (MDR) bacteria such as
methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis (MRSE)
occur frequently in community-acquired severe infections. Pandrug-resistant (PDR) strains of
Gram-negative such as E. coli and Pseudomonas aeruginosa could not been eradicated by most
antibiotics [3]. It is urgent to develop a new generation of antibacterial agents for combating drug
resistance [4-7]. Host-defense peptides (HDPs), natural cationic amphiphilic peptides, are found
in all organisms and act as the first line of nonspecific defense against a variety of pathogens
including bacteria, fungi, and virus [8-10]. Unlike traditional antibiotics targeting and breaking
down intracellular components of bacteria or specific cell wall, HDPs interact with bacterial
membranes firstly by taking advantage of electrostatic interaction between their cationic groups
and negatively charged bacterial membranes [2, 11]. After that, the hydrophobic residues of HDPs
interact with the fatty acyl tails of membrane phospholipids, causing the bacterial membrane
penetration, depolarization, and disruption [12]. HDPs interact with bacterial membranes with
biophysical force and involve no defined specific membrane targets, endowing HDPs with lower
antibiotic resistance compared to traditional antibiotics [13, 14]. Consequently, HDPs could be a
potentially viable strategy to develop a new antibiotic agent [15-17]. However, intrinsic drawbacks
30

are limiting the development of HDPs as antibiotics for practical application, such as susceptibility
to proteolytic degradation and low-to-moderate activity [18, 19]. Non-natural peptidomimetics
antibiotic agents that mimic the structure and action of HDPs, such as α-peptides [20], β-peptides
[21], peptoids [22], arylamide oligomers [23], cationic polymers [24], and others [25] have been
explored in the past several decades [26-30]. In the past years, our group has reported a class of
antimicrobial peptidomimetics “γ-AApeptide” which mimics the amphipathic structure of HDPs
[31-34]. Among them, some short lipid γ- AA hybrid peptides, bearing α-amino acid residues and
γ-AA units, displayed potent and broad activity against Gram-positive and/or Gram-negative
bacteria [31, 35-37]. Recently, we found the strategy of dimerization could lead to even more
potent activity with a smaller size [38, 39]. Herein, we report the application of the dimerization
strategy to design a new series of small molecular mimics of HDPs.

Figure 3. 1 General structures of canonical α-peptides, γ-AApeptides, sulfono-γ- AApeptides, and
α/sulfono-γ-AA hybrid peptides.
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Figure 3. 2 (A) Structure of the monomer lipo-α/sulfono-γ-AA hybrid peptides [40]. (B) Structure
of the dimeric lipo-α/sulfono-γ-AA hybrid peptides [33].

Results and Discussion
The dimeric lipo-α/sulfono-γ-AA hybrid peptides were synthesized on the solid phase and purified
by HPLC [35]. The ratios of cationic groups, length of lipid tails, and hydrophobic groups in
mimicking the amphipathic structure of HDPs were investigated.
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Table 3. 1 Structures and Antibacterial activity of compounds 1–20.The bacteria used were
methicillin-resistant S. aureus (MRSA) (ATCC 33591), methicillin-resistant S. epidermidis
(MRSE) (RP62A), E. coli (ATCC 25922), P. aeruginosa (ATCC 27853). ND: not determined.
Hemolysis activity was not measured for peptidomimetics show antimicrobial activity less than
three tested strains.
MIC (μg/mL)
Gram-positive

Hemolysis

Gram-negative

(HC50,

Structure
μg/mL)

#
E.

P.

coli

aeruginosa

MRSA MRSE

3-6

3-6

6-12.5

NA

3-6

6-12.5

>250

NA

ND

1

612.5

2
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Table 3.1 (Continued)

12.5NA

NA

NA

ND

25
3

NA

NA

NA

NA

ND

NA

NA

NA

NA

ND

3-6

NA

12.5-25

>250

4

5

612.5
6
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Table 3.1 (Continued)

7

3-6

NA

NA

NA

ND

NA

ND

12.5NA

NA
25

8

NA

6-12.5

NA

NA

ND

NA

NA

NA

NA

ND

9

10
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Table 3.1 (Continued)

12.56-12.5

NA

NA

ND

25
11

NA

NA

NA

NA

ND

3-6

3-6

1.5-3

NA

ND

12.5-

6NA

ND

12

13

3-6
25

14
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12.5

Table 3.1 (Continued)

66-12.5

NA

NA

ND

NA

ND

12.5
15

63-6

NA
12.5

16

3-6

3-6

3-6

3-6

>250

3-6

1.5-3

3-6

NA

>250

17

18
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Table 3.1 (Continued)

3-6

1.5-3

1.5-3

NA

>250

3-6

3-6

NA

>250

19

3-6
20

The antimicrobial activity of hybrid peptides was tested and are listed in Table 3.1. Many
compounds show good antibacterial activity against both Gram-positive and Gram-negative
bacteria, and the relationship between structure and antibacterial activity could lead us to further
develop the class of peptidomimetics in the future. Compound 1, containing dimeric sulfonoAApeptide building blocks bearing a chiral positively charged side chain and a hydrophobic
phenyl sulfonamido group as well as a C12 lipid tail, already exhibited good activity toward both
Gram-positive and Gram-negative bacteria. The structural difference between compound 1 and 2
is that 2 has a C16 lipid tail instead of C12, but the activity dropped significantly. It is consistent
with our previous findings that the length of lipid tail plays an important role to influence the
compound to interact with bacterial membrane [26, 27]. It seems that C12 lipid tail is the optimal
length as compound 3-5 which possess short lipid tails but did not show any antibacterial activity
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[22, 27]. We next synthesized the compound 6-8 which do not contain the terminal lysine amino
acid residues on the two arms. Interestingly, these compounds were much less potent compared
with compound 1, indicating the importance of cationic charge. The compounds 9 and 10, bearing
two lipid tails instead of one, however, their almost completely abolished their antibacterial
activity. It is interesting that compound 11, bearing a sulfono--AApeptide building block in each
arm with switched positions for both side chains compared with 1, virtually completely lost its
antibacterial activity, even though 11 contains identical ratio of cationic to hydrophobic groups as
compound 1. The result may indicate that the arrangement of hydrophobic and cationic patches in
the compound is crucial for its antimicrobial activity. Next, we synthesized the compound 12
containing just cationic groups as arms. To our surprise, the compound did not exhibit any
antimicrobial activity, suggesting that the ratio of cationic groups and hydrophobic groups is
critical. Furthermore, we kept molecular scaffold of 1 and only changed hydrophobic groups on
the sulfono side chain. Among them, the compound 17, containing two chlorophenyl sulfonyl side
chains, shows the most potent antibacterial activity toward both Gram-positive and Gram-negative
all tested bacteria strains. It is possible that the chlorophenyl groups could have both hydrophobic
and polar interactions with bacterial membranes, thus enhancing the ability to compromise the
membranes.
Based on compounds’ HPLC retention time (RT), we estimated the amphiphilicity of these
compounds. From the HPLC data (Table 3.2 in Experiment Section), the most potent
compound 17 has a RT of 19.70 min. These compounds with RT shorter than 18 min
(compounds 3,4,5, and 12) did not display any antibacterial activity. Compounds bearing RTs
ranging from 18 min to 19.70 min, increased antibacterial activity is accompanied by increased
RTs. The antibacterial activity of compounds started to decrease when the RT value more than
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19.70 min. From the analysis, it is consistent with our previous statement that the balance of
hydrophobicity and hydrophilicity plays an important role in influence antibacterial activity [41].
After that, hemolytic assay was conducted to evaluate the therapeutic potential of these compounds
[42]. As shown in Table 3.1, for breakdown 50% of human red blood cells, compound 17’s
concentration must be greater than 250 μg/mL. The concentration is more than 40-fold of
compound 17’s antibacterial activity concentration toward all four tested bacteria strains. It attests
the lead compound 17 has low toxicity.
As we hypothesized the dimeric lipo-α/sulfono-γ-AA hybrid peptides could mimic the mechanism
of HDPs, these peptides should be able to disrupt the bacteria membrane and eradicate bacteria
rapidly [43]. The time-kill study was then conducted to explore the bacterial killing kinetics for
most potent compound 17. As shown in Figure 3.3, at the lowest concentration of 6 μg/mL,
compound 17 could kill MRSA in 2h, whereas at a higher concentration such as 12.5 μg/mL and
25 μg/mL, MRSA could even be eradicated in roughly 1 h. At concentration 40 μg/mL and 50
μg/mL of 17, all the MRSA were in just half an hour. Killing E. coli is comparatively slower,
however, compound 17 could still effectively arrest the growth of E. coli in lower concentration,
and at the higher concentration 40 μg/mL and 50 μg/mL, all E. coli could be eradicated in 6 h.
These results suggest that compound 17 could kill both MRSA and E. coli in a similar manner
compared to HDPs.
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Figure 3. 3 Time-kill plots of 17 against MRSA (A) and E. coli (B).

Subsequently, fluorescent microscopy was conducted to further study the compounds’ effect to
compromise bacterial membranes. In this assay, DAPI could stain bacterial cells’ membranes with
blue fluorescence irrespective of their viability. However, PI can only stain the dead or impaired
cells’ membranes with red fluorescence. As shown in Figure 3.4, the control, without treatment
with compound 17, shows blue fluorescence with DAPI (a1 and a3) but no fluorescence with PI(
b1 and b3), proving that both MRSA and E. coli bacteria’s membranes were intact. After
incubating MRSA and E. coli with compound 17 for 2h, Both DAPI and PI channels (a2, b2, a4,
b4) were observed with strong fluorescence. It demonstrates that the membranes of both MRSA
and E. coli were compromised.
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Figure 3. 4 Fluorescence micrographs of MRSA and E. coli that are treated or not treated with 12
μg/mL of compound 17 for 2 h: (a1) control, no treatment, PI stained; (b1) control, no treatment,
DAPI stained; (c1) control, no treatment, PI and DAPI channel merge; (a2) MRSA treatment with
17, PI stained; (b2) MRSA treatment with 17, DAPI stained; (c2) MRSA treatment with 17, PI and
DAPI channel merge;(a3) control, no treatment, PI stained; (b3) control, no treatment, DAPI
stained; (c3) control, no treatment, PI and DAPI channel merge; (a4) E. coli treatment with 17, PI
stained; (b4) E. coli treatment with 17, DAPI stained; (c4) E. coli treatment with 17, PI and DAPI
channel merge.

To further test whether the compound 17 mimics the mechanism of action of HDPs, we carried
out membrane depolarization. DiSC3(5) is a membrane-potential voltage-sensitive dye that could
accumulate on hyperpolarized membranes and translocate into the lipid bilayer. The weak
fluorescence is observed in living bacterial cells due to self-quenching, however, the fluorescence
intensity would increase dramatically when the bacterial membrane potential is lost Bacteria were
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incubated with DiSC3(5) in 30 mins, after then immediately treated bacteria with compound 17 in
different concentrations of 1×MIC, 2×MIC, and 4×MIC. As shown in Figure 3.5, both MRSA and
E. coli show dramatic enhancement of fluorescence intensity after treatment of compound 17, and
the fluorescence intensity increase is in concentration-dependent. The results demonstrated
compound 17 could disrupt the bacterial membrane.

Figure 3. 5 Membrane depolarization of MRSA (A) and E. coli (B). Negative control is the culture
without antibacterial treatment. The experiment was repeated three times with duplicates each
time.

Furthermore, TEM study was conducted to visualize if our compounds can damage bacteria’s
membranes as the TEM micrograph is a straightforward way to appear in cell membrane
morphology. As shown in Figure 3.6A and Figure 3.6C, the control, MRSA and E. coli had intact
membrane structures. After treatment with 12 μg/ mL concentration of compound 17 for 2 h, both
MRSA and E. coli membranes have been damaged, even some cells became debris (Figure
3.6Band Figure 3.6D). The result visually proves that the compound 17 can destroy bacterial cell
membranes again.
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Figure 3. 6 Observation of cell membrane damage by transmission electron micrographs (TEM):
(A) MRSA cells without any antibacterial treatment (control); (B) MRSA cells treated with
compound 17 at 12 μg/mL; (C) E. coli cells without any antibacterial treatment (control); (D) E.
coli after treatment with compound 17 at 12 μg/mL.

It is known that most bacterial infections are followed by the biofilm formation, and bacteria in
biofilm are much harder to kill than independent cells since biofilms have potent resistance to
antibiotics [44]. As such, we conducted the biofilm study to evaluate compound 17’s inhibitory
effect on biofilm formation of MRSA and E. coli. As shown in Figure 3.7, at just concentration
of 0.094 μg/mL, almost 50% of biofilm formation of MRSA been inhibited by compound 17. For
biofilm formation of E. coli, the suppress capability of compound 17 was not that strong, even
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though, at a concentration of 0.188 μg/mL, the compound 17 could inhibit around 40% of biofilm
formation of E. coli. This reinforces the potential of compound 17 as the novel antibiotic agent.

Figure 3. 7 Biological activity of 17 in the inhibition of a biofilm by MRSA(A) and E. coli (B).

Conclusion
In summary, we designed and synthesized a series of short dimeric lipo-α/sulfono-γ-AA hybrid
peptides through dimerization strategy at ease. The lead compounds showed potent bacteria-killing
efficacy against a series of Gram-positive and Gram-negative bacteria with low hemolytic toxicity,
suggesting the therapeutic potential of these compounds to be applied for clinical use.
Fluorescence microscopy, TEM, and membrane depolarization studies demonstrated that the lead
compound 17 could kill bacteria by interrupting with bacteria membrane as mimic the mechanism
of action of HDPs. Compound 17 also has a good ability to inhibit biofilm formation. The further
development of the class of dimerized γ-AA peptides could lead to a new generation of
antibacterial agents.
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Experiment Section
General Information
Rink-amide resin (0.64mmol/g,200-400 mesh) and Fmoc protected α-amino acids were purchased
from Chem-impex Int’l Inc. Solvents, coupling reagents, and other chemicals were purchased from
either Fisher Scientific or Sigma-Aldrich in reagent grade. Column chromatography was carried
out with silica gel (200−300 mesh). All compounds were synthesized by using solid-phase peptide
synthesis. The compound synthesized in a peptide reaction vessel clamped on a Burrell wristaction shaker and purified on a High-Performance Liquid Chromatography (HPLC) system with
both analytical and preparative functions. The final product’s molecular weight was confirmed by
using a Bruker AutoFlex MALDI-TOF mass spectrometer, the desired final pure products were
dried on a Labcono lyophilizer.
Synthesis of Sulfono-γ-AApeptide Building Blocks
The syntheses of the sulfono-γ-AApeptide Building Blocks was followed the previously reported
procedure [33].

Figure 3. 8 Synthetic scheme of linker.
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Figure 3. 9 Sulfono-γ-AA peptide building blocks and amino acid used in the study.
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Synthesis of Desired Short Dimeric Lipo-α/sulfono-γ-AA Hybrid Peptides

Figure 3. 8 General synthetic scheme of Dimeric lipo-α/sulfono-γ-AA peptides.

Figure 3. 9 Typical synthetic route for compound 9 and 10.
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Figure 3. 10 Typical synthetic route for compound 8.

Minimum Inhibitory Concentrations (MICs) Antimicrobial Assays [41]
We tested the antimicrobial activity of the 20 compounds against on four different bacteria strains
including MRSA (ATCC 33591), MRSE (RP62A), P. aeruginosa (ATCC27853), and E.
coli (ATCC 25922). The experiment was completed by the following protocol. The bacteria cells
in 5ml of tryptic soy broth (TSB) buffer were inoculated at 37℃ overnight. Then diluted the
bacteria culture 100 times and allowed to grow to the mid-logarithmic phase. 50 µL of these
bacteria suspension were added every well in 96 well plate followed by 50 µL of different
concentrations of dimeric lipo-α/γ-AA peptides diluted with the same TSB medium. Incubated the
mixtures at 37 °C for 18 h, the Minimum Inhibitory Concentrations (MICs) were recorded by
measuring optical density at the absorption at 600 nm wavelength on a Biotek Synergy HT
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microtiter plate reader. MICs are the lowest concentrations of the compounds which can inhibit
the bacteria growth. Results were repeated three times with duplicates each time.
Hemolytic Assays [38]
Fresh human red blood cell (hRBCs) was washed with 1xPBS and centrifuged at 3000 rpm for 10
mins twice, discarded the top clear supernatant, diluted the bottom hRBCs layer to 5% v/v
suspension in 1 x PBS. 50mL of the diluted hRBCs solution added in 96-well plate each well as
well as 50 mL 2-fold serial dilution lead compounds. Then incubated at 37 °C for 1 hour. After
that, centrifuge the mixture solution for 10 minutes at 3000 rpm. Added 100 mL PBS to 30 mL
supernatant and read the absorbance of the mixture on a Biotek Synergy HT plate reader at the
wavelength of 410 nm and 540 nm. The hemolysis activity was determined by the formula: %
hemolysis=(Abssample−AbsPBS)/ (AbsTriton−Abs PBS) ×100. Used 1 x PBS as the negative
control and 1% and 5% Triton X-100 as the positive control.
Time-kill Assays [33]
The time-kill assay was performed to determine the efficacy of the best compound 17 against
MRSA (Gram-positive) and E. coli (Gram-negative). The bacteria were grown overnight in TSB
at 37℃ to the mid-logarithmic phase and diluted to 1 x 106 CFU/mL, the bacteria were incubated
with different concentrations (6g/mL,12.5g/mL,25g/mL,40g/mL,50g/mL) of compound 17
at different time points (0. 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6 h). The suspensions were plated
onto agar plates. The plates were incubated overnight at 37℃ and then colonies were counted. The
assays were done three times on different occasions.
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Fluorescence microscopy [24]
Two dyes were used in the study: DAPI (4’,6-diamidino-2-phenylindole dihydrochloride) and PI
(propidium iodide). DAPI has a good ability to dye any bacterial cells, however, PI can only dye
dead cells because it can only pass through damaged membranes. Bacteria were cultured to midlogarithmic phase at 37℃ and diluted 100 folds, then incubated compound 17 for 2 hours at 37℃.(
for the controls, no compound added) collected the cell pellets after centrifuged for 15min at 3000
rpm, then washed with PBS and incubated with DAPI (10 mg/mL) for 15min on ice in the dark.
Next, washed twice with PBS to remove excess dye. Repeated the procedure with PI(5mg/mL)
and controls. A Zeiss Axio Imager Z1 optical microscope (100×) was then used to observe the
cells.
Bacterial Membrane Depolarization Assay [33]
Collected the bacterial cells when it grown to mid-log phase, then washed with 5mM HEPES and
5 mM glucose. The bacteria were re-suspended in a 1:1:1 ratio (108CFU/mL) of 5 mM glucose, 5
mM HEPES, and 100 mM KCL solution. 200 mM of bacterial suspension solution and 2 mM of
3,3′-Dipropylthiadicarbocyanine iodide DiSC3(5) were added in a 96-well plate at 37 °C. After
that, monitored the fluorescence of the suspension for a half-hour at 37 °C at the excitation
wavelength of 622 nm and the emission wavelength of 670 nm. Added the compound 17 to the
wells immediately when the minimum value of fluorescence was reached. The increase in
fluorescence was observed. The experiment was repeated three times.
Transmission electron Microscopy (TEM) [41]
Bacterial cells grew in Mid log phase and incubated with compound 17 in TSB at 37°C for 2h.
Then centrifuged the mixture at 1000g for 10 min and collected the bacterial pellets at the bottom
51

of the centrifuge tube. Washed the bacterial pellets with PBS four times, after that, dissolve the
bacteria in deionized water. The samples without added compound 17 were control samples.
Added a drop of each sample’s solution on the carbon-coated Cu grids and wiped off the excess
sample with filter paper. Let the grids dry for about 1 h and ready for TEM study. TEM images
were taken under FEI Morgagni 268D TEM with an Olympus MegaView III camera on the
microscope.
Inhibition of Biofilms [42]
Growing bacteria (MRSA and E. coli) for 12 h at 37 °C. Diluted compound 17 with 50 µL 2-fold
serial dilution in 96-wells plate, follow added 50 µL of diluted bacterial medium (1 × 106
CFU/mL) to each vial. Then after incubated 48 h at 37 °C, gently washed the wells with TSB three
times to remove unattached biofilms. The wells dried after around 24 h, used 125uL 0.1% crystal
violet solution to stain the attached biofilms for 10 min. Then washed with TSB three times to
remove excess stained solution and let the wells dried again. After that, added 200 µL 30% acetic
acid to each vial to dissolve stain for 10 min. Transferred the dissolved solution to a new 96-wells
plate and recorded the OD reading at 595 nm wavelength.
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Table 3. 2 MALDI analysis of Dimeric lipo-α/sulfono-γ-AA hybrid peptides
Dimeric lipo-α/sulfono-γ-AA
peptides
1

Exact Mass

Observed (MALDI-TOF)

1367.82

1368.91

2

1423.88

1424.89

3

1339.79

1340.81

4

1311.76

1312.83

5

1283.72

1285.14

6

1111.63

1112.71

7

1167.69

1169.11

8

842.55

843.91

9

1293.80

1295.33

10

1405.92

1406.93

11

1311.76

1312.85

12

1017.62

1018.71

13

1423.96

1425.19

14

1367.82

1368.97

15

1399.81

1400.95

16

1429.76

1430.87

17

1407.71

1408.74

18

1495.61

1496.71

19

1439.82

1440.85

20

1439.82

1440.85
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Table 3. 3 HPLC purities and retention time of Dimeric lipo-α/sulfono-γ-AA peptides. The
gradient eluting method of 5% to 100% of solvent B (0.1% TFA in acetonitrile) in A (0.1% TFA
in water) was performed.
Dimeric lipo-α/sulfono-γ-AA
peptides

Purity trace after HPLC
purification (%)

Retention Time (min)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

100.00
99.86
100.00
98.98
99.50
99.97
98.59
99.91
99.07
99.84
100.00
100.00
99.99
99.96
99.85
99.92
100.00
99.75
99.90
99.91

19.09
22.99
17.70
15.66
13.73
21.73
26.59
22.12
29.53
39.18
18.74
17.39
19.60
18.75
18.52
18.53
19.70
19.55
19.75
19.64
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CHAPTER 4: DIMERIC γ-AA PEPTIDES INHIBITORS OF Aβ AGGREGATION
Introduction
Alzheimer's disease is the most common form of dementia, a general term for memory loss and
other cognitive abilities serious enough to interfere with daily life [1]. At least 50 million
worldwide people are living with Alzheimer's Disease (AD) [2]. It is very important to detect AD
at an early-stage to effectively control the disease [3]. Research has shown that one of the
etiological factors of Alzheimer’s disease is the abnormal aggregation of amyloid-beta(Aβ) which
can lead to neurodegeneration long before the first symptoms of AD start to become visible [4-6].
Identify inhibitors that can early detect and prevent Aβ aggregation is crucial for therapy AD
[7].To date, some inhibitors, such as natural products [8], constrained peptides [9], small molecules
[10] , and engineered peptides[11] have been reported. Even though these inhibitors are specific
in their activity, but a good number of them are dual inhibitors such that they can inhibit Aβ
aggregation of multiple classes of proteins [8, 12]. It is a highly significant need to develop a novel
specifically binding anti-Aβ aggregation detector or inhibitor.
Our group has reported a new class of peptidomimetic termed in “γ-AApeptides” (Figure 4.1)[13].
The unique backbone of γ-AApeptides is derived from γ-PNA which are superior resistance to
proteolysis and potential for peptide mimicry [14]. N-acylated-N-aminoethyl amino acid units
consist of the γ-AApeptides [15]. The repeating unit of the AApeptide backbone has two side
chains in each unit, one is from an α-amino acid side chain, another one is from a tertiary amide
[16]. The unique backbone makes γ-AApeptides enormous chemical diversity since the γ60

AApeptides contain the same number of side functional groups as conventional peptides with the
same length of backbones. These make the γ-AApeptides as an ideal candidate for drug discovery
[17].

Figure 4. 1 General structures of canonical α-peptides, γ-AApeptides.

In our previous work, we reported a small molecular ligand that inhibits Aβ aggregation, HW155-1, which was the lead compound identified from a one-bead-one-compound (OBOC) γAApeptide combinatorial library [18]. The control peptide KLVFF is the hydrophobic core
residues 16-20 of the Aβ peptide can inhibit Aβ aggregation both in vitro and in vivo (Figure 4.2)
[19-21]. HW-155-1 exhibited 100-fold more effective than KLVFF in inhibiting Aβ aggregation
[18]. To further explore the intervention of AD, we optimized the HW-155-1 structure by using
the dimeric strategy to synthesis compound LLW- B-135 and investigated its ability to detect and
prevent Aβ aggregation.

Figure 4. 2 The identified γ-AApeptide from the OBOC library screening (HW-155-1) and the
control peptide KLVFF [18].( The figure was reproduced with permission of Royal Society of
Chemistry.)
61

Results and Discussion
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Figure 4. 3 Structure of LLW-B-135.

The LLW-B-135 was synthesized by solid-phase and purified by HPLC [22]. Compound LLWB-135 cytotoxicity against N2a/APP cells was determined by MTT assay. The N2a/APP cells are
mouse neuroblastoma N2a cells which stably express human mutant amyloid precursor protein
(APP). Aβ protein is hydrolyzed from APP, so the N2a/APP cells are an ideal cell model for
studying Aβ aggregation in vitro. From Figure 4.4, we observed that cell viability was affected by
LLW-B-135 in a significant dose-dependent reduction manner. LLW-B-135 at a concentration of
20 μg/mL reduced the cell viability by 54%, whereas at 100 μg/mL, the cell viability reduced to
almost 6% with respect to the control treatment. The result will as a guide to determine LLW-B135’s concentration for the future mice behavioral test.
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Figure 4. 4 MTT assay of compound LLW-B-135 against N2a/APP cells.

Inhibition of Aβ Aggregation in Vitro
Aβ42 peptide incubated with 20 μM concentration of LLW-B-135 or HW-155-1 at 37℃ for 3 days
and analyzed by western blot. As shown in Figure 4.5, the Aβ42 control without any drug contained
oligomer after 3 days, as we expected, there is obviously inhibition of Aβ42 aggregation which is
treated with HW-155-1 or LLW-B-135. The Aβ42 incubated with dimeric compound LLW-B-135
showed less oligomer and more dimer of Aβ42 compared to HW-155-1. This demonstrates that
LLW-B-135

has

stronger

inhibition

compared

to

the

monomer

HW-155-1.

The

immunohistochemical staining assay confirms the suppose.
After that, we synthesized the LLW-B-135 labeled with iFluor™ 750 maleimide (structure see
Figure 4.9) to confirm LLW-B-135 can detect the amyloid-beta plaque. As shown in Figure
4.7(1), as we expected, only the transgenic (TG) mice brain which contains amyloid-beta plaque
stained with LLW-B-135-maleimide showed strong red fluorescence, there is no any fluorescence
been detected in Figure 4.7(1C) even stained with LLW-B-135-maleimide since there is no
amyloid-beta plaque in no transgenic mice brain. Congo red staining method is a universal
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method used to detect amyloid deposits in the brain tissue of amyloid precursor protein
transgenic mice and human Alzheimer's tissue [23]. LLW-B-135-maleimide staining
results are consistent with Congo red (Figure 4.7(2)). The consequence demonstrated that LLWB-135-maleimide has the potential as an Aβ aggregation detector for the early-stage of AD detect.

Figure 4. 5 Western blot analyses of inhibition of Aβ aggregation in vitro.

Figure 4. 6 Immunohistochemical staining assay. (A) Mouse brain tissue was incubated
with/without 25 µM HW-155-1 /LLW-B-135 overnight and stained with antibodies. (B)
quantification of the density and strength of stains.
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Figure 4. 7 (1) LLW-B-135-maleimide staining: A. TG mice brain LLW-B-135-maleimide
stained. B. TG mice brain without staining. C. No transgenic (NTG)mice brain LLW-B-135maleimide stained. (2) Congo red comparison: A.TG mice brain LLW-B-135-maleimide stained.
B. NTG mice brain LLW-B-135-maleimide stained.

Conclusion and Prospect
In summary, dimeric γ-AApeptide LLW-B-135 could detect, prevent, and even disassemble Aβ
aggregation. The compound can be a potential candidate for the Aβ aggregation probe or
therapeutic agent for the treatment of Alzheimer’s disease. We are currently working on the mice
behavioral test to research the effect of LLW-B-135 on Alzheimer’s disease in vivo.

Experimental Section
General Information
Rink-amide resin (0.64mmol/g,200-400 mesh) and Fmoc protected α-amino acids were purchased
from Chem-impex Int’l Inc. Solvents, coupling reagents, and other chemicals were purchased from
either Fisher Scientific or Sigma-Aldrich at reagent grade. Column chromatography was carried
out with silica gel (200−300 mesh). All compounds were synthesized by using solid-phase peptide
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synthesis. The compound synthesized in a peptide reaction vessel clamped on a Burrell wristaction shaker and purified on a High-Performance Liquid Chromatography (HPLC) system with
both analytical and preparative functions. The final product’s molecular weight was confirmed by
using a Bruker AutoFlex MALDI-TOF mass spectrometer, the desired final pure products were
dried on a Labcono lyophilizer.
Synthesis of γ-AApeptide Building Blocks
The syntheses of the γ-AApeptide Building Blocks (Figure 4.8) was followed the previously
reported procedure [24].

Figure 4. 8 γ-AApeptide building blocks used in the study.

Figure 4. 9 Structure of LLW-B-135 labeled with iFluor™ 750 maleimide.
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Figure 4. 10 Synthetic scheme of LLW-B-135.

MTT Assay [25]
N2a cells in good condition were plated in 96-well plates at concentration of 5× 103 cells /well
with five replicates for 24h at 37 °C, removed the growth medium and added different
concentrations of compound LLW-B-135 with no FBS medium incubated for 24h at 37 °C. After
that, added 10 μL of Kit-8 (CCK-8) solution inn each well and incubated 2 hours, cell viability can
be measured by using playreader read the absorbance at 450 nm. Experiments were repeated three
times.
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Western Blot Assay [26]
Aβ42 peptide incubated with 20 μM concentration of LLW-B-135 or HW-155-1 in 1xPBS at 37℃
for 3 days. There is no drug added to the Aβ42 control. Collected proteins samples and loaded onto
10% Bis-Tris Gel and electrophoresed, then transferred onto a polyvinylidene fluoride membrane,
Immobilon-P (Burlington, MA, USA, Millipore Sigma, Cat# IPVH00010, Lot# R6EA8481H).
After incubating the membranes with 0.2% block buffer for 1 h at room temperature, the
membranes were treated with A8 antibody which is Aβ specific antibody diluted in 0.2% at 4 °C
overnight. After washing and incubating with secondary antibodies, labeled proteins were
visualized with ECL-reagent.
Immunohistochemical staining Assay [27]
Mouse brain tissue was incubated with/without 25 µM HW-155-1 /LLW-B-135 overnight. Half
of the brain were removed and fixed in 4% Paraformaldehyde, and a series of sucrose solutions
were applied dehydration and sectioned at 25 µm thickness. The sections were incubated with
primary antibodies and then streptavidin and biotin-HRP for conjugation (1hr, RT). Sections were
then washed and developed in 0.05% diaminobenzidine, 0.5% Ni2+, and 0.03% H2O2 dissolved
in TBS. Finally, sections were washed (1x TBS, 2 times with 1x PBS; 5min, RT) and mounted on
slides, dehydrated in a series of ethyl alcohol solutions, and coverslipped.
LLW-B-135-maleimide Staining [28]
Dissolved the LLW-B-135-maleimide in PBS to a final concentration of 100 uM. Mice brain
sliced were stained in LLW-B-135-maleimide solution for 3h in room temperature and then
mounted on the specimen. Slides were hydrated by taking it through a series of ethyl alcohol
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solutions. The slides were then rinsed, and the results were captured by the Keyence BZ-X810
fluorescence microscope with an appropriate filter.
Congo Red Comparison Staining [28]
Congo red was used for the amyloid-β plaque staining. Brain tissue sections were mounted on
slides and left to dry overnight. The slides were stained in 1% Congo Red solution in 50% ethyl
alcohol for 30 seconds at room temperature. The slides were then dehydrated and coverslipped.
results were captured by the Keyence BZ-X810 fluorescence microscope.
References
[1] J.A. Hardy, G.A. Higgins, Alzheimer's disease: the amyloid cascade hypothesis, Science, 256
(1992) 184+.
[2] I. Javed, G. Peng, Y. Xing, T. Yu, M. Zhao, A. Kakinen, A. Faridi, C.L. Parish, F. Ding, T.P.
Davis, P.C. Ke, S. Lin, Inhibition of amyloid beta toxicity in zebrafish with a chaperone-gold
nanoparticle dual strategy, Nat Commun, 10 (2019) 3780.
[3] W.G. Rosen, R.C. Mohs, K.L. Davis, A new rating scale for Alzheimer's disease, The American
Journal of Psychiatry, 141 (1984) 1356-1364.
[4] N. Suzuki, T. Cheung, X. Cai, A. Odaka, L. Otvos, C. Eckman, T. Golde, S. Younkin, An
increased percentage of long amyloid beta protein secreted by familial amyloid beta protein
precursor (beta APP717) mutants, 264 (1994) 1336-1340.
[5] N. Amakiri, A. Kubosumi, J. Tran, P.H. Reddy, Amyloid Beta and MicroRNAs in Alzheimer’s
Disease, 13 (2019).
[6] T. Hartmann, Intracellular biology of Alzheimer’s disease amyloid beta peptide, European
Archives of Psychiatry and Clinical Neuroscience, 249 (1999) 291-298.
69

[7] Y.Q. Leong, K.Y. Ng, S.M. Chye, A.P.K. Ling, R.Y. Koh, Mechanisms of action of amyloidbeta and its precursor protein in neuronal cell death, Metabolic Brain Disease, 35 (2020) 11-30.
[8] B. Ren, Y. Liu, Y. Zhang, Y. Cai, X. Gong, Y. Chang, L. Xu, J. Zheng, Genistein: A Dual
Inhibitor of Both Amyloid β and Human Islet Amylin Peptides, ACS chemical neuroscience, 9
(2018) 1215-1224.
[9] K. Muthusamy, P.I. Arvidsson, P. Govender, H.G. Kruger, G.E. Maguire, T. Govender, Design
and study of peptide-based inhibitors of amylin cytotoxicity, Bioorganic & medicinal chemistry
letters, 20 (2010) 1360-1362.
[10] S. Bahramikia, R. Yazdanparast, Inhibition of human islet amyloid polypeptide or amylin
aggregation by two manganese-salen derivatives, European journal of pharmacology, 707 (2013)
17-25.
[11] Y. Mao, L. Yu, M. Mao, C. Ma, L. Qu, Design and study of lipopeptide inhibitors on
preventing aggregation of human islet amyloid polypeptide residues 11-20, Journal of peptide
science : an official publication of the European Peptide Society, 24 (2018).
[12] Q. Wang, X. Yu, K. Patal, R. Hu, S. Chuang, G. Zhang, J. Zheng, Tanshinones inhibit amyloid
aggregation by amyloid-β peptide, disaggregate amyloid fibrils, and protect cultured cells, ACS
chemical neuroscience, 4 (2013) 1004-1015.
[13] Y. Shi, P. Teng, P. Sang, F. She, L. Wei, J. Cai, γ-AApeptides: design, structure, and
applications, Acc. Chem. Res., 49 (2016) 428.
[14] Y. Niu, R.E. Wang, H. Wu, J. Cai, Recent Development of Small Antimicrobial
Peptidomimetics, Future Med. Chem., 4 (2012) 1853.
[15] H. Wu, Q. Qiao, P. Teng, Y. Hu, D. Antoniadis, X. Zuo, J. Cai, New Class of Heterogeneous
Helical Peptidomimetics, Org. Lett., 17 (2015) 3524.

70

[16] P. Sang, Y. Shi, P. Teng, A. Cao, H. Xu, Q. Li, J. Cai, Antimicrobial AApeptides, Curr Top
Med Chem, 17 (2017) 1266-1279.
[17] Y. Niu, R.E. Wang, H. Wu, J. Cai, Recent development of small antimicrobial
peptidomimetics, 4 (2012) 1853-1862.
[18] H. Wu, Y. Li, G. Bai, Y. Niu, Q. Qiao, J.D. Tipton, C. Cao, J. Cai, γ-AApeptide-based smallmolecule ligands that inhibit Aβ aggregation, Chemical Communications, 50 (2014) 5206-5208.
[19] P.-N. Cheng, C. Liu, M. Zhao, D. Eisenberg, J.S. Nowick, Amyloid β-sheet mimics that
antagonize protein aggregation and reduce amyloid toxicity, Nat Chem, 4 (2012) 927-933.
[20] C. Soto, E.M. Sigurdsson, L. Morelli, R. Asok Kumar, E.M. Castaño, B. Frangione, β-sheet
breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for
Alzheimer's therapy, Nature Medicine, 4 (1998) 822-826.
[21] K. Pauwels, T.L. Williams, K.L. Morris, W. Jonckheere, A. Vandersteen, G. Kelly, J.
Schymkowitz, F. Rousseau, A. Pastore, L.C. Serpell, K. Broersen, Structural basis for increased
toxicity of pathological aβ42:aβ40 ratios in Alzheimer disease, The Journal of biological chemistry,
287 (2012) 5650-5660.
[22] F. She, A. Nimmagadda, P. Teng, M. Su, X. Zuo, J. Cai, Helical 1:1 α/Sulfono-γ-AA
Heterogeneous Peptides with Antibacterial Activity, Biomacromolecules, 17 (2016) 1854-1859.
[23] D.M. Wilcock, M.N. Gordon, D. Morgan, Quantification of cerebral amyloid angiopathy and
parenchymal amyloid plaques with Congo red histochemical stain, Nature Protocols, 1 (2006)
1591-1595.
[24] H. Wu, Y. Niu, S. Padhee, R.E. Wang, Y. Li, Q. Qiao, G. Bai, C. Cao, J. Cai, Design and
synthesis of unprecedented cyclic γ-AApeptides for antimicrobial development, Chem. Sci., 3
(2012) 2570.

71

[25] J. van Meerloo, G.J.L. Kaspers, J. Cloos, Cell Sensitivity Assays: The MTT Assay, in: I.A.
Cree (Ed.) Cancer Cell Culture: Methods and Protocols, Humana Press, Totowa, NJ, 2011, pp.
237-245.
[26] N. Shen, G. Song, H. Yang, X. Lin, B. Brown, Y. Hong, J. Cai, C. Cao, Identifying the
Pathological Domain of Alpha- Synuclein as a Therapeutic for Parkinson’s Disease, 20 (2019)
2338.
[27] S.M. de la Monte, Y.K. Sohn, J.R. Wands, Correlates of p53- and Fas (CD95)-mediated
apoptosis in Alzheimer's disease, Journal of the Neurological Sciences, 152 (1997) 73-83.
[28] S.D. Styren, R.L. Hamilton, G.C. Styren, W.E. Klunk, X-34, A Fluorescent Derivative of
Congo Red: A Novel Histochemical Stain for Alzheimer's Disease Pathology, Journal of
Histochemistry & Cytochemistry, 48 (2000) 1223-1232.

72

CHAPTER 5: PEPTIDOMIMETIC-BASED ANTIBODY SURROGATE FOR EGFR
Introduction
Epidermal Growth Factor Receptor (EGFR) is the receptor for epithelial growth factor (EGF) cell
proliferation and signal transduction [1]. EGFR is located on the cell membrane surface and is
activated by binding to ligands, including EGF and transforming growth factor α [2]. EGFR is
converted from monomer to dimer after activation, followed by its kinase pathway been activated
[3]. This autophosphorylation can guide downstream phosphorylation to induce cell proliferation
[4]. Previously studies have shown that there is high or abnormal expression of EGFR in many
tumors [5-9]. EGFR is related to the tumor cell proliferation, angiogenesis, tumor invasion,
metastasis and apoptosis [10]. Overexpression of EGFR plays an important role in the evolution
of malignant tumors [11-13]. It is essential to target the EGFR signaling pathway and block EGFR
in relevant cancers therapy [14].
Significant efforts have been extended to develop EGFR inhibitors [15-17]. Some of the inhibitors
such as cetuximab [18] , Panitumumab [19] ,and others [20] already use for therapy some cancers
[21, 22]. However, the side effects of the EGFR-targeted therapies have not totally understood yet.
The most common side effects are dermatologic toxicities and diarrhea [23, 24]. Although side
effects caused by EGFR are generally classified as moderate, but they are usually chronic and may
significantly impact the patient’s quality of life [25-27]. As such, it is vital to develop the novel
efficient EGFR inhibitor which could overcome these side effects.
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Our group designed the new no-natural sequence-specific peptidomimetics backbone termed in
“γ-AApeptides” which derived from γ-chiral PNAs (Figure 5.1)[28]. Compared to conventional
α-peptides, γ-AApeptides can project identical number of side functional groups with same length
of backbones [29]. Furthermore, γ-AApeptides backbone is remarkable stability which highly
resistant to proteolysis [30]. The chemodiversity and protease resistance of γ-AApeptides make it
as an ideal candidate as molecular probes or therapeutic agents [31]. Our previously published
demonstrated that one-bead-one compound (OBOC) linear γ-AApeptide combinatorial libraries
can inhibit Aβ aggregation and disrupt STAT3/DNA interaction [32, 33]. Based on the structural
chemistry, head to tail backbone cyclization γ-AApeptides can enhance conformational rigidity
and constraints compared with the linear γ-AApeptides [34]. We designed and synthesized onebead-two-compounds (OBTC) cyclic γ-AApeptide library to against EGFR and found the lead
compound M-2-5. The lead compound exhibit inhibition to EGFR both in vitro and in vivo. We
are undergoing on optimized the M-2-5 structure by using the dimeric strategy to synthesis
compounds LLW-C-30 to improve the binding affinity with EGFR.

Figure 5. 1 General structures of canonical α-peptides, γ-AApeptides.

Our Group Previously Work
As shown in Figure 5.2, we synthesized the cyclic library by split and pool method through solid
phase as previously report. We used TentaGel bead which can separate into two layers, the inner
layer is attached linear decoding α-peptides, the outer layer is tagged with the desired cyclic γ-
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AApeptide. For the cyclic γ-AApeptide, we included five N-alloc-protected γ-AApeptide building
blocks, and eight acylating agents. The linear decoding α-peptides consist of seven α-amino acid
residues which were uniquely related to each side chain of the cyclic γ-AApeptides and were used
for encoding the structure of the cyclic γ-AApeptides. In theory, the library would totally contain
320000 compounds [35].
Then, the library screening against for the EGFR protein was performed. We first did the
prescreening to avoid nonspecific binding. Then, we did the screening by incubate the library
beads with recombinant human EGFR protein, followed by treatment with anti-human monoclonal
antibody labeled with Dylight 488. At end five strong red fluorescence beads were picked up under
a fluorescence microscope. After that, we cleavaged the linear encoding peptides from beads and
decoding the cyclic sequence by MALDI MS/MS unambiguously [35]. We resynthesized the five
sequences with fluorescein labeled on Rink-amide resin and tested their ability to bind to EGFR
in vitro by fluorescence polarization assay. There are two compounds M-2-2-F and M-2-5-F
exhibited strong binding affinity toward EGFR with a KD of 0.554 μM and 0.426 μM. (Figure
5.3) We hypothesized that our cyclic lead compounds could inhibit EGFR dimerization to restrain
its autophosphorylation and suppress the downstream pathways such as AKT and ERK (Figure
5.2c)).
Then, M-2-2 and M-2-5 compounds incubated with A549 cells which overexpresses EGFR for
24h and analyzed cell lysates by western blotting. As shown in Figure 5.3 (C)(D), The M-2-5’s
ability to inhibit EGFR phosphorylation is stronger compared to M-2-2. It is consistent with the
fluorescence polarization assay. As we expected, M-2-5 inhibition of EGFR phosphorylation is in
a concentration-dependent and the downstream activation of phosphorylation of both AKT and
ERK were also inhibited (Figure 5.3 (E)(F)). This confirmed the conjecture that our lead
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compound can inhibit EGFR autophosphorylation and suppress the downstream pathways. The
vivo test result emphasized it (Figure 5.4).

Figure 5. 2 (a) Structure and chemical diversity of the library. (b) A schematic illustration of the
screening method. (The figure was reproduced with permission of American Chemical Society)
(c) EGFR signaling and inhibition pathway.

Figure 5. 3 (A) Structures of M-2-2 and M-2-5. (B) Kd of compounds to EGFR. (C)(D) Western
blot analyses of A549 cell lysates following EGF stimulation and hits treatment. (E)(F) Western
blot analyses of A549 cell lysates following EGF stimulation and M-2-5 treatment in different
concentration.
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Figure 5. 4 M-2-5 suppression of tumor growth in nude mice.

Undergoing Now

Figure 5. 5 (A) Structure of the cyclic- γ -AApeptides (B) Artificial antibody based on cyclicγAApeptides.
The strong binding affinity of M-2-5 (Figure 5.3) prompted us to move forward for the design of
γ-AApeptides based artificial antibody. As shown in Figure 5.5, since M-2-5 could mimic a
binding loop domain of the “Y” shaped monoclonal antibody [36], we could make a dimer of M2-5 by attached a linker to mimic the two binding loop domains of antibody. As shown in Figure
5.6, an antibody-like dimer of M-2-5 could be designed in a very straightforward manner, which
took advantage of the alkyne-azide click reaction [37] with high reactivity for dimerization.
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Briefly, azide modified cyclic γ-AApeptide M-2-5-N3 bearing a PEG linker to improve the
solubility was synthesized on solid phase synthesis and then purified by HPLC, which could be
dimerized with di-alkyne linker by click reaction to form LLW-C-30. that could possess the
similar function as antibody. The length of PEG linker could be changed, thereby making it easily
accessible to further optimize and enhance binding activity of this class of artificial antibody in
the future.

Figure 5. 6 The design and synthesis of LLW-C-30.

Prospect
In the future, we will test LLW-C-30 to EGFR by SPR assay, the binding affinity with EGFR
should be stronger compared with M-2-5. After we got positive result from SPR assay, we will
conduct western blotting assays, wound-healing assay, transwell assay, in vivo assays and others.
Hoping LLW-C-30 or its analogues can development into outstanding candidates for inhibiting
EGFR effectively with little side effects.
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Experimental Section
General Information
Rink-amide resin (0.64mmol/g,200-400 mesh) and Fmoc protected α-amino acids were purchased
from Chem-impex Int’l Inc. Solvents, coupling reagents, and other chemicals were purchased from
either Fisher Scientific or Sigma-Aldrich at reagent grade. Column chromatography was carried
out with silica gel (200−300 mesh). All compounds were synthesized by using solid-phase peptide
synthesis. The compound synthesized in a peptide reaction vessel clamped on a Burrell wristaction shaker and purified on a High-Performance Liquid Chromatography (HPLC) system with
both analytical and preparative functions. The final product’s molecular weight was confirmed by
using a Bruker AutoFlex MALDI-TOF mass spectrometer, the desired final pure products were
dried on a Labcono lyophilizer.
Synthesis of γ-AApeptide Building Blocks
The syntheses of the γ-AApeptide Building Blocks (Figure 5.7) was followed the previously
reported procedure.

Figure 5. 7 γ-AApeptide building blocks used in the study.
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Figure 5. 8 Synthetic scheme of linker.

Synthesis of M-2-5-N3
The compound was synthesized following the standard solid phase peptide synthesis protocol by
using Rink-amide resin. the Fmoc-Lys(Dde)-OH was first attached to the Rink amide resin.
Followed by removed Fmoc protection group (20% Piperidine in DMF for 10min x2), 2 equivalent
of the Fmoc protected N-alloc-protected γ-AApeptide building blocks, 4 equivalent of HOBT and
DIC in DMF were added to react for 4 h. The Alloc protecting group was removed by Pd(PPh3)4
(8 mg, 0.007 mmol) and Me2NH·BH3 (25 mg, 0.42 mmol) in 3 mL DCM (10 min × 2), 2
equivalent of the carboxylic acids, 4 equivalent of HOBT and DIC in DMF were added to react
for overnight. Repetition of the reaction cycle until the desired γ-AApeptides were synthesized.
After the γ-AApeptides were cyclized, the Dde group was removed. Fmoc-NH-(PEG)n-COOH
(2equiv), 4 equivalent of HOBT and DIC in DMF were added to the resin and shaken for 4 h. After
that, removed Fmoc protection group and attached 2-Azidoacetic acid with HOBT and DIC in
DMF. The cyclic γ-peptide was cleaved by 1:1 (v/v) DCM/TFA containing 2% triisopropylsilane.
Collect the cleavage solution and concentration by vacuum and purified by Waters HPLC system,
followed by lyophilization to obtain the pure product.
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Synthesis of C-30

After we got pure M-2-5-N3, we mixed the 1 equivalent of M-5-N3 with 0.5 equivalent of linker
dissolved in DMSO and DI water solution , followed by added 1.5 equivalent of copper(II) sulfate
and 3 equivalent of sodium ascorbate reacted for overnight . Monitored and purified the desired
compound by Waters HPLC system.
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CHAPTER 6: THE ACTIVITY OF α/SULFONO- γ-AA HYBRID PEPTIDES THAT
MIMIC GIP
Introduction
Type 2 diabetes is the most common diabetes in the world [1]. It is caused by defects in the
secretion of insulin by pancreatic B cells or insulin resistance [2]. Traditional medicine for type 2
diabetes needs to be taken or injected multiple times a day which lets patients have poor
compliance [3]. Gastric inhibitory polypeptide (GIP) and glucagon-like peptide (GLP)-1 are
inhibiting hormones of the secretin family of hormones [4]. The main role of these two peptides is
to stimulate insulin secretion to lower blood sugar [5]. However, the rapid degradation (circulating
half-life of 2–5 min) of incretin hormones in vivo by the enzyme dipeptidyl-peptidase IV (DPP-4)
and poor membrane permeability are essential drawbacks to limit the development of GIP and
GIP-1 [2, 6]. In recent years, GLP-1 receptor agonists[7] and DPP-4 inhibitors[8] are two main
research fields for invent new antidiabetic drugs [9, 10]. However, the development of GIP analogs
is underestimated. In the past years, our groups have developed a new class of peptidomimetics
termed as “γ-AApeptides” because they are comprised of N-acylated-N-aminoethyl amino acids
(Figure 6.1) [11, 12]. The γ-AA peptides’ backbones are stable and highly resistant to proteolysis.
Recently, we introduced α/sulfono-γ-AA peptides as a new class of mimetics which is sulfonyl
chlorides react with the secondary nitrogen on the backbone [13-15].The sulfono-γ-AA peptides
can adopt the α-helix-like conformation in solution, sulfonamide groups are bulky and may induce
a curvature conformation of the backbone. Furthermore, an α/sulfono-γ-AA peptide theoretically
projects the same number of side chains as the α-peptide of the same length [16, 17]. These
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advantages make α/sulfono-γ-AA peptides a stronger potential candidate for peptidomimetic.
Here, we report the α/sulfono- γ-AA hybrid peptides for the GIP peptide mimicking.

Figure 6. 1 General structures of canonical α-peptides, γ-AApeptides, sulfono-γ- AApeptides, and
α/sulfono-γ-AA hybrid peptides.

Results and Discussion
Design and Biological Activity of α/Sulfono-γ-AA Hybrid Peptides
GIP is a linear peptide composed of 42 amino acids. Base on previously published papers, analysis
of GIP and GIPR interaction reveals the GIP (1-32) shows the identical displacement of
radiolabeled GIP from the binding site compared to native GIP (1-42). So our research are focusing
on GIP (1-32) peptide [18, 19]. We hypothesized that molecules project functional groups
analogous to GIP’s critical residues could bind to GIP receptor (GIPR) as well as extend the halflife time. From previous studies, we knew that the modification of the C-terminus of the GIP has
little influence on the interaction of GIP with its receptor [20]. The α/sulfono-γ-AA hybrid peptides
were synthesized on the solid phase and purified by HPLC [18]. The 14 compounds structures and
binding affinity to the GIP receptor (GIPR) shown in Table 6.1 and Figure 6.2. Compounds 91
A1 and 91 A2 are the natural occurring GIP controls. Semaglutide is a new GLP-1 analog drug,
which can greatly control the blood sugar level of patients with type 2 diabetes in clinical trials,
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we used it as a positive control in this research. From Figure 6.2 A, 91 B1, 91 B2, 91 C1, and 91
C2 compounds are not competitive to Semaglutide. We changed positions 2 and 4 amino acids to
phenylsulfonyl- γ-AA building blocks of peptides 91 C2 and 91 C2 resulted in at least twofold
decrease in binding affinity compared to 91B2 (Table 6.1 and Figure 6.2A). Consistent with
previous findings that the portion of the GIP peptide from amino acids 1 to 11 is crucial for ligandreceptor interaction with the GIP receptor [19]. Furthermore, for peptides 140 1A, 140 1N, 140
2A, and 140 2N, we replaced Ala with 2-Aminoisobutyric acid in site 2 to improve the biological
stability without influence the interaction with the receptor. Also, replacement C-terminal with
only one of our sulfono- γ-AA peptide Lys building block which is amphipathic structure helps to
improve the binding affinity with the receptor. From Figure 6.2, peptide 140 2A with capped Nterminal which binding affinity is almost 900-fold of Semaglutide, it suggests that the N-terminal
portion of GIP can be removed without impairing the activity of the molecule [20]. For the
compounds 38-1 to 38-5, we attached PEG lipo tails to improve the stability of the compounds
without lower binding affinity too much. As we expected, 38-4 exhibits significant binding affinity
compared to Semaglutide.
91
A1
91
A2
91B
1

Figure 6. 2 Structures of GIP and α/sulfono- γ-AA hybrid peptides.
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Figure 6. 2 Structures of GIP and α/sulfono- γ-AA hybrid peptides. (Continued)
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Figure 6. 2 Structures of GIP and α/sulfono- γ-AA hybrid peptides. (Continued)
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Figure 6. 3 Vitro GIPR Activation Assay.

Figure 6. 4 The serum stability of 91A1,140-2A, and 38-4 were determined in 25% serum (v/v).
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Stability Study
As stated before, the critical problem in limit the development of GIP analogs due to their rapid
degradation. According from the in vitro assay result, peptides 140-2A and 38-4 were chosen as
the lead candidates. We further evaluated the stability of the two compounds in comparison with
the natural GIP peptides in human serum. The compounds stability is essential for their further
biological activity. We performed the assays by incubated the 0.5 mg/mL concentration of peptides
in a 25% (V:V) aqueous: human serum solution. From Figure 5.2, the natural GIP peptide 91A1
is very unstable even started to decompose as it mixture with the serum. Both 140-2A and 91 A1
were degraded completely after 24 hours in presence of serum. However, as we expected, 38-4
showed remarkable stability in solution. This demonstrates that the PEG lipo tails can enhance the
compound stability.
Conclusion and Prospect
In conclusion, we have developed a series of α/sulfono-γ-AA hybrid peptides mimic the structure
and function of the GIP. The unnatural peptidomimetics exhibit the good stability, exploration of
the lead peptide function and mechanism to GIPR is currently underway.
Experimental Procedure
General Information
Rink-amide resin (0.64mmol/g,200-400 mesh) and Fmoc protected α-amino acids were purchased
from Chem-impex Int’l Inc. Solvents, coupling reagents, and other chemicals were purchased from
either Fisher Scientific or Sigma-Aldrich at reagent grade. Column chromatography was carried
out with silica gel (200−300 mesh). All compounds were synthesized by using solid-phase peptide
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synthesis. The compound synthesized in a peptide reaction vessel clamped on a Burrell wristaction shaker and purified on a High-Performance Liquid Chromatography (HPLC) system with
both analytical and preparative functions. The final product’s molecular weight was confirmed by
using a Bruker AutoFlex MALDI-TOF mass spectrometer, the desired final pure products were
dried on a Labcono lyophilizer.
Synthesis of Sulfono-γ-AApeptide Building Blocks
The syntheses of the sulfono-γ-AApeptide Building Blocks (Figure 6.5) was followed the
previously reported procedure [21].

Figure 6. 5 Sulfono-γ-AApeptide building blocks used in the study
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Synthetic Route of Sulfono- α/γ-AA Hybrid Peptides
Sulfono- α/γ-AA hybrid peptides sequences were synthesized following the standard solid phase
peptide synthesis protocol by using Rink-amide resin [22]. Swelled the resin in N,N′dimethylformamide (DMF) for 5 min before use. For every coupling step, 20% Piperidine in DMF
for 10min (×2) was used to remove the Fmoc (9-fluorenyl methoxycarbonyl) protecting group,
then washed with DCM (×3) and DMF (×3). 2 equivalent of the Fmoc protected regular amino
acid/sulfono-γ-AApeptide building block, 4 equivalent of HOBT and DIC in DMF were added to
react for 4 h. Repetition of the reaction cycle until the desired sulfono-γ-AApeptides were
synthesized. For compounds 38-2,38-3,38-4, and 38-5 which contained a lipo tails. Final step was
to remove Dde protection groups afterthe desired sulfono-γ-AApeptides was synthesized.
Followed with reactionwith Fmoc protected PEG/Glu-OH/, and octadecanedioic acid mono-tertbutyl ester followed by deFmoc protecting group each time. Cleaved of the final sequence by using
trifluoroacetic acid (TFA)/DCM (3 ml, 1:1, v/v) mixture solution for 2 hours. Collect the cleavage
solution and concentration by vacuum and purified by Waters HPLC system, followed by
lyophilization to obtain the pure product.
In Vitro GIPR Activation Assay [16]
Incubation of different concentrations of the tested compounds with Chok1 cells which
overexpressed GIPR for 30 min at 37°C. The dose-response is plotted as the HTRF ratio
(EM665/615 nm). Data points are the mean ± SEM of ≥3 independent experiments with duplicate
measurements for each experiment. Half maximal effective concentration (EC50) values were
calculated for each duplicate and the mean values for cAMP EC50 ± SEM are reported in the table.
Serum Stability Assays [16]
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Determined the serum stabilities of peptides by using 25%(V: V) aqueous pooled human serum.
Dissolved peptides in H2O/CH3CN (70:30 v:v) and diluted in serum at a final concentration of
0.5 mg/mL and incubated at 37 °C for 24h. Followed by adding 50 uL solution to 50 uL ACN on
ice for 20 min. After that, centrifugation of the solution at 4°C for 10 min. The supernatant was
then diluted with H2O (0.1% TFA) at a final concentration of 0.1 mg/mL and analyzed by
reversed-phase HPLC. The amount of intact peptide was estimated by integrating the area under
the corresponding elution peak monitored at 215 nm.
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APPENDIX A: PUBLISHING RIGHTS

Figure A1 Antibacterial activity of lipo-α/sulfono-γ-AA hybrid peptides.
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Figure A2 (a) Structure and chemical diversity of the library.
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Figure A3 Synthesis of the thioether bridged one-bead–two-compound macrocyclic γ-AApeptide
library.
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Figure A4 General antimicrobial resistance mechanisms.
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Figure A5 Use of combinatorial chemistry to generate a compound library. This diagram shows
one technique, split mix synthesis, for generating large numbers of compounds.
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Figure A5 Use of combinatorial chemistry to generate a compound library. This diagram shows
one technique, split mix synthesis, for generating large numbers of compounds. (Continued)
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Figure A5 Use of combinatorial chemistry to generate a compound library. This diagram shows
one technique, split mix synthesis, for generating large numbers of compounds. (Continued)
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Figure A5 Use of combinatorial chemistry to generate a compound library. This diagram shows
one technique, split mix synthesis, for generating large numbers of compounds. (Continued).
105

Figure A5 Use of combinatorial chemistry to generate a compound library. This diagram shows
one technique, split mix synthesis, for generating large numbers of compounds. (Continued)
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Figure A6 The preparation of γ-AApeptide OBOC library. The diversity of the library: totally 4
× 5 × 4 × 5 × 4 × 5 × 4 × 5 = 160,000 compounds. Beads: TentaGel MB NH2, particle size: 140 170 μm, capacity: 0.5 nmol/bead.
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Figure A6 The preparation of γ-AApeptide OBOC library. The diversity of the library: totally
4 × 5 × 4 × 5 × 4 × 5 × 4 × 5 = 160,000 compounds. Beads: TentaGel MB NH2, particle size:
140 - 170 μm, capacity: 0.5 nmol/bead. (Continued)
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Figure A6 The preparation of γ-AApeptide OBOC library. The diversity of the library: totally
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Figure A7 Models of peptide-induced membrane disruption or interfacial activity.
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Figure A7 Models of peptide-induced membrane disruption or interfacial activity. (Continued)
112

Figure A7 Models of peptide-induced membrane disruption or interfacial activity. (Continued)
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Figure A7 Models of peptide-induced membrane disruption or interfacial activity. (Continued)
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Figure A7 Models of peptide-induced membrane disruption or interfacial activity. (Continued)
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Figure A7 Models of peptide-induced membrane disruption or interfacial activity. (Continued)
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